Physician profile
Lara E Morgan
NPI 1578899043
$11,159.14
in general payments reported to CMS, 2019-2025
52 companies · $1,857 in 2025
The $1,857 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,783 · 2022: $2,157 · 2023: $2,787 · 2024: $2,575 · 2025: $1,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,182 · Education: $37.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,181.55 |
| Education | $37.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,958.17 | 2021-2025 | |
| Amgen INC. | $941.22 | 2021-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $930.90 | 2021-2025 | |
| Novo Nordisk INC | $693.47 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $672.80 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $634.21 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $604.76 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.49 | 2021-2025 | Jardiance, Stiolto Respimat |
| Lilly USA, LLC | $457.95 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $403.31 | 2023-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $302.84 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $274.83 | 2022-2024 | |
| Astellas Pharma US INC | $265.84 | 2021-2025 | Veozah |
| Merck Sharp & Dohme LLC | $194.27 | 2021-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.59 | 2022-2025 | Xifaxan, Trulance |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $183.86 | 2024-2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $157.77 | 2023-2024 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.90 | 2022-2025 | Caplyta |
| Inogen, INC. | $145.13 | 2023-2025 | Inogen |
| Global Blood Therapeutics, INC. | $112.94 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $101.55 | 2021-2025 | Zoryve |
| Eisai INC. | $96.70 | 2021 | |
| Horizon Therapeutics Plc | $96.18 | 2021-2023 | Krystexxa |
| Exact Sciences Corporation | $91.23 | 2023-2024 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $82.02 | 2023-2025 | Tirosint, Licart, Licart |
| E.R. Squibb & Sons, L.L.C. | $73.66 | 2022-2024 | Eliquis |
| Seqirus USA INC | $71.51 | 2022-2025 | Flucelvax, Fluad |
| Biohaven Pharmaceutical Holding Company Ltd. | $69.65 | 2022 | |
| Jazz Pharmaceuticals INC. | $60.38 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $57.55 | 2021 | |
| Axsome Therapeutics, INC. | $57.47 | 2024-2025 | Sunosi |
| Organon LLC | $49.49 | 2022-2023 | Nexplanon |
| Gilead Sciences, INC. | $48.00 | 2021-2022 | |
| Dexcom, INC. | $43.80 | 2024-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $43.67 | 2022-2023 | |
| Ironwood Pharmaceuticals, INC | $41.92 | 2023 | Linzess |
| Amarin Pharma, INC. | $35.66 | 2021-2022 | |
| Alkermes, INC. | $25.75 | 2022 | |
| Lundbeck LLC | $24.08 | 2024 | Rexulti |
| Medtronic, INC. | $23.07 | 2023 | Intellis Adaptivestim |
| Phadia US INC. | $22.56 | 2025 | Immunocap |
| Sanofi Pasteur INC. | $21.14 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.42 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.31 | 2022 | |
| Millicent US INC | $19.17 | 2024 | Intrarosa, Femring |
| Exeltis, USA INC. | $18.34 | 2024 | Slynd |
| Aimmune Therapeutics, INC. | $17.70 | 2025 | Zenpep |
| Viiv Healthcare Company | $17.32 | 2025 | Apretude |
| Bardy Diagnostics, INC. | $15.02 | 2021 | |
| Clarus Therapeutics INC. | $14.80 | 2021 | |
| Supernus Pharmaceuticals, INC. | $14.15 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lara Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.